Targeting Ferredoxin 1-mediated metabolic vulnerabilities could offer novel strategies to selectively inhibit tumor growth while sparing normal cells, thereby improving the efficacy of cancer treatment and overcoming therapeutic resistance. This evidence concerns the gene FDX1 and neoplasm.